ABSTRACT
INTRODUCTION: Patients with peritoneal metastases (PM) from hepatocellular carcinoma (HCC) often experience a rapid demise even after a complete removal of intrahepatic tumour. Localised PM may now be adequately controlled and managed with cytoreductive surgery (CRS). TREATMENT: Three patients underwent CRS for HCC PM. OUTCOME: The first patient survived 21 months from the time of CRS and is alive with the disease. The second patient died 4 months after CRS. The third patient survived 10 months since CRS and is also alive with the disease. Collectively, the survival of 24 patients with HCC PM extracted through a collective literature review who were treated with cytoreductive surgery had 1- and 2-year survival percentages of 83% and 71%, respectively. CONCLUSION: Careful selection of patients with localised disease to the peritoneal cavity for CRS, taking into consideration the performance status, liver function and tumour biology may lead to a successful outcome in patients with HCC PM.
Subject(s)
Carcinoma, Hepatocellular/pathology , Liver Neoplasms/pathology , Peritoneal Neoplasms/secondary , Carcinoma, Hepatocellular/drug therapy , Carcinoma, Hepatocellular/surgery , Fatal Outcome , Female , Humans , Liver Neoplasms/drug therapy , Liver Neoplasms/surgery , Male , Middle Aged , Peritoneal Neoplasms/drug therapy , Peritoneal Neoplasms/surgery , Peritoneum/pathology , Young AdultABSTRACT
Percutaneous radiofrequency ablation (RFA) is an alternate treatment modality for pulmonary metastasis in non-surgical candidates. Four patients not suitable for surgery underwent percutaneous RFA for pulmonary metastases from leiomyosarcoma. Success of RFA was assessed with computed tomography (CT). The median length from the radiographic diagnosis of metastatic pulmonary disease (CT-scan) from the primary tumor diagnosis was 67.0 months with a range of 15.0-81.0 months. The median disease free interval following RFA was 19.0 months with a range of 4.0-35.0 months. Three of four patients underwent the procedure uneventfully. RFA is a safe and minimally invasive intervention in non-surgical candidates with sarcoma pulmonary metastases.